{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T21:16:45Z","timestamp":1766006205027,"version":"3.48.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":51,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ero.2025.11.020","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T01:30:03Z","timestamp":1765503003000},"page":"484-487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The treatment landscape in axial spondyloarthritis\u2014do we need new therapies?"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-6015","authenticated-orcid":false,"given":"Denis","family":"Poddubnyy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10089","key":"10.1016\/j.ero.2025.11.020_bib0001","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ero.2025.11.020_bib0002","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard-2023-225185","article-title":"Goodbye to the term \u2018ankylosing spondylitis\u2019, hello \u2018axial spondyloarthritis\u2019: time to embrace the ASAS-defined nomenclature","volume":"83","author":"van der Heijde","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ero.2025.11.020_bib0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ero.2025.11.020_bib0004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ero.2025.11.020_bib0005","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3899\/jrheum.2024-1303","article-title":"Residual disease activity and burden of disease in Canadian patients with axial spondyloarthritis: results from a multiregistry analysis (UNISON-Axial SpA)","volume":"52","author":"Choquette","year":"2025","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.ero.2025.11.020_bib0006","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/art.42852","article-title":"Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: results from a head-to-head randomized phase IIIb study","volume":"76","author":"Baraliakos","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ero.2025.11.020_bib0007","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/ard-2022-223298","article-title":"Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis","volume":"82","author":"Webers","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ero.2025.11.020_bib0008","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41584-025-01254-5","article-title":"Understanding the causes of treatment failure is crucial for the management of axial spondyloarthritis","volume":"21","author":"Poddubnyy","year":"2025","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.ero.2025.11.020_bib0009","doi-asserted-by":"crossref","first-page":"e652","DOI":"10.1016\/S2665-9913(25)00108-0","article-title":"The imaging crisis in axial spondyloarthritis","volume":"7","author":"Diekhoff","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"10.1016\/j.ero.2025.11.020_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005422","article-title":"Effect of depressive symptoms on treatment response in patients with axSpA: data from the RABBIT-SpA register","volume":"11","author":"Reich","year":"2025","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ero.2025.11.020_bib0011","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13075-020-02301-0","article-title":"The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study","volume":"22","author":"Redeker","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.ero.2025.11.020_bib0012","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1136\/annrheumdis-2019-216143","article-title":"Determining factors related to poor quality of life in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS)","volume":"79","author":"Macfarlane","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10289","key":"10.1016\/j.ero.2025.11.020_bib0013","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/S0140-6736(21)00392-5","article-title":"Nociplastic pain: towards an understanding of prevalent pain conditions","volume":"397","author":"Fitzcharles","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ero.2025.11.020_bib0014","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.semarthrit.2021.02.007","article-title":"Fibromyalgia and obesity: a comprehensive systematic review and meta-analysis","volume":"51","author":"D\u2019Onghia","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ero.2025.11.020_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-004009","article-title":"Association of nociplastic and neuropathic pain components with the presence of residual symptoms in patients with axial spondyloarthritis receiving biological disease-modifying antirheumatic drugs","volume":"10","author":"Al Mohamad","year":"2024","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.ero.2025.11.020_bib0016","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ard.2025.01.035","article-title":"The Assessment of SpondyloArthritis International Society (ASAS) consensus-based expert definition of difficult-to-manage, including treatment-refractory, axial spondyloarthritis","volume":"84","author":"Poddubnyy","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ero.2025.11.020_bib0017","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1093\/rheumatology\/keaf120","article-title":"Exploring difficult-to-manage axial spondyloarthritis: results from a Dutch clinical practice registry","volume":"64","author":"Smits","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"10289","key":"10.1016\/j.ero.2025.11.020_bib0018","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","article-title":"Chronic pain: an update on burden, best practices, and new advances","volume":"397","author":"Cohen","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ero.2025.11.020_bib0019","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1016\/S2665-9913(23)00324-7","article-title":"Nociceptive, neuropathic, or nociplastic low back pain? The low back pain phenotyping (BACPAP) consortium\u2019s international and multidisciplinary consensus recommendations","volume":"6","author":"Nijs","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ero.2025.11.020_bib0020","doi-asserted-by":"crossref","first-page":"pnaf089","DOI":"10.1093\/pm\/pnaf089","article-title":"Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine","author":"Lederman","year":"2025","journal-title":"Pain Med"},{"issue":"1","key":"10.1016\/j.ero.2025.11.020_bib0021","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41927-024-00373-y","article-title":"The efficacy of tofacitinib combined with bDMARDs in the treatment of ankylosing spondylitis patients with inadequate response to bDMARDs: a retrospective study","volume":"8","author":"Chang","year":"2024","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.ero.2025.11.020_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1283251","article-title":"Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain","volume":"14","author":"Valero-Mart\u00ednez","year":"2023","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.ero.2025.11.020_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103865","article-title":"Combination targeted therapy with two biologic\/targeted synthetic DMARDs in 1200 patients with immune mediated inflammatory diseases. A systematic literature review for current landscape in safety and efficacy","volume":"24","author":"Lignou","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.ero.2025.11.020_bib0024","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1134\/S1607672925700140","article-title":"The efficacy and safety of BCD-180, an anti-TRBV9+ T cell monoclonal antibody, in patients with active radiographic axial spondyloarthritis: 36-week results from the randomized, double-blind, placebo-controlled phase 2 clinical study ELEFTA","volume":"522","author":"Nasonov","year":"2025","journal-title":"Dokl Biochem Biophys"},{"issue":"17","key":"10.1016\/j.ero.2025.11.020_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713335","article-title":"ERAP1 and ERAP2 haplotypes influence suboptimal HLA-B*27:05-restricted anti-viral CD8+ T cell responses cross-reactive to self-epitopes","volume":"24","author":"Tedeschi","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"616","key":"10.1016\/j.ero.2025.11.020_bib0026","doi-asserted-by":"crossref","first-page":"eabg1210","DOI":"10.1126\/scitranslmed.abg1210","article-title":"Macrophage migration inhibitory factor drives pathology in a mouse model of spondyloarthritis and is associated with human disease","volume":"13","author":"Nakamura","year":"2021","journal-title":"Sci Transl Med"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S305070812500120X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S305070812500120X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T21:13:37Z","timestamp":1766006017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S305070812500120X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S305070812500120X"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2025.11.020","relation":{},"ISSN":["3050-7081"],"issn-type":[{"type":"print","value":"3050-7081"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The treatment landscape in axial spondyloarthritis\u2014do we need new therapies?","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2025.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}